Company news

NeOnc Technologies Holdings, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

NeOnc’s Ambitious Brain Cancer Plans are Setting the Stage

October 30, 2026

NeOnc Targets Major Brain Cancer Trial Expansion with 500 Patients Across 30 Hospitals in Three Countries

October 26, 2026

NeOnc Breaks Through Key Levels, as Brain-Cancer Stock’s Catalysts Continue

October 23, 2026

NeOnc Heads to Fox Business as Brain Cancer Milestones Put Its Mission in the Spotlight

October 22, 2026

NeOnc Technologies to Be Featured on Health Uncensored with Dr. Drew to Discuss Reaching Brain Tumors Without Surgery or Systemic Chemotherapy

October 22, 2026

NeOnc Technologies to Be Featured on Health Uncensored with Dr. Drew to Discuss Reaching Brain Tumors Without Surgery or Systemic Chemotherapy

October 22, 2026

NeOnc's Brain Cancer Efforts Bring Hope as FDA Meeting Approaches

October 21, 2026

NeOnc Deepens Abu Dhabi Research Ties as Its Brain Cancer Story Moves Forward

October 21, 2026

NeOnc Technologies and the Department of Health – Abu Dhabi Sign MoU to Advance Brain Cancer Research and Proposed Clinical Collaboration

October 21, 2026

Forget the Ugly Sweaters and Ugly Charts, NeOnc is Ready for Catalyst Season

October 20, 2026

NeOnc's Most Challenging Test Yet: Compassionate-Use Update Puts NEO100's Potential in Focus

October 16, 2026

NeOnc’s Boldest Test Yet: Child’s Early Improvement Puts NEO100 in the Spotlight with Compassionate-Use Milestone

October 16, 2026

NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi

October 16, 2026

NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi

October 16, 2026

From Shaq to Musk: The Power Appointment Effect

October 15, 2026

UAE Banking Heavyweight Joins NeOnc as Global Brain-Cancer Drug Development Advances

October 15, 2026

NeOnc CEO Amir F. Heshmatpour to Address Global Life Sciences Investment at Abu Dhabi Future Health Summit 2026

October 15, 2026

NeOnc CEO Amir F. Heshmatpour to Address Global Life Sciences Investment at Abu Dhabi Future Health Summit 2026

October 15, 2026

NeOnc Strengthens Boardroom Firepower as Abu Dhabi Opens a New Path for Brain Cancer Drug Development

October 14, 2026

NeOnc Technologies Appoints Ali Alabedin to Its Board of Directors

October 14, 2026

NeOnc among Names with 2026 Breakthroughs that Offer New Hope in the Fight Against Cancer

October 7, 2026

NeOnc’s FDA Catalyst Run Could Give NTHI a Serious Jolt

October 6, 2026

NeOnc’s Powerful Brain Cancer Pipeline Advances

September 29, 2026

NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212

September 28, 2026

NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution

September 17, 2026

NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results

September 16, 2026

NeOnc Technologies Holdings, Inc. Announces Pricing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules with New and Existing Institutional Investors

September 9, 2026

Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26

August 13, 2026

NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x

August 12, 2026

NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence

August 11, 2026

NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout

August 10, 2026

NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

August 10, 2026

NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors

July 27, 2026

NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition

July 15, 2026

NeOnc Ignites Explosive Summer: 4 New Research Reports + UAE/Dubai Drug Approval Fuel Breakout Momentum

June 23, 2026

NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone

June 23, 2026

WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy

June 22, 2026

WSTPR Catalyst Watch: NeOnc Strengthens Capital Position Ahead of Potentially Transformational Neuro-Oncology Updates

June 15, 2026

NeOnc Provides Business Update and Reports Q1 2026 Financial Results

May 18, 2026

NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts

May 5, 2026

NeOnc Technologies Holdings, Inc. Announces ~ $300,000 in Insider Purchases of NTHI Stock by Chairman and CEO; Company Provides Context on 2025 Financial Results

April 14, 2026

NeOnc Provides Business Update and Reports Q4 2025 Financial Results

March 31, 2026

NeOnc Technologies Appoints David Choi as Chief Accounting Officer

March 12, 2026

Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

March 12, 2026

NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

March 3, 2026

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity

February 26, 2026

NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management

January 30, 2026

Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

January 9, 2026

NeOnc Technologies Reports Updated Clinical Results

December 15, 2025

NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors

December 1, 2025

Older news releases →

Calls

Decks

The 5 newest of 10 decks. Every deck is listed under its year.